The Food and Drug Administration has approved a fixed-dose triple inhaler containing budesonide/glycopyrrolate/formoterol fumarate for maintenance treatment of asthma in patients aged 12 years and older, according to the manufacturer in a press release. The single-inhaler regimen combines a corticosteroid and a long-acting beta2-agonist with a long-acting muscarinic antagonist. The inhaler is intended for asthma patients not adequately controlled on dual therapy. Approval was based on phase III trials, which showed statistically significant improvements in …
Read More